- MEASURE-AD was a real-world study of moderate to severe
atopic dermatitis patients across 28 countries designed to assess
the multidimensional burdens that diagnosed patients
face1-3
- Additional findings show that lower clinical burden and work
impairment had a positive association with quality of life and
lower disease severity scores1
- Atopic dermatitis, also known as eczema, impacts up to an
estimated 10 percent of adults and 25 percent of children globally
and causes significant physical, psychological and economic
impact4-7
NORTH
CHICAGO, Ill., Sept. 8,
2022 /PRNewswire/ -- An analysis from AbbVie's (NYSE:
ABBV) three-year, 28-country MEASURE-AD study revealed that people
living with moderate to severe atopic dermatitis (an
immune-mediated skin disease) who are not receiving systemic
therapy had greater clinical, psychosocial and economic burdens
compared to those receiving systemic therapy.1 A
separate analysis from the MEASURE-AD study demonstrated that
better quality of life – as measured by Dermatology Life
Quality Index (DLQI) scores – and lower disease severity
scores were associated with lower clinical burden and work
impairment.2 Results from the MEASURE-AD subanalyses
were featured at the 31st European Academy of
Dermatology and Venereology (EADV) Hybrid Congress onsite in
Milan and online from September 7-10 as a poster and an oral
presentation.
"Results from MEASURE-AD broaden awareness of the continued
burden that people living with atopic dermatitis experience every
day and of the potential link between disease severity, treatment
approach and overall impact on patient-reported quality of life,"
said Juan Francisco Silvestre, M.D.,
attending dermatologist, General University Hospital of Alicante in
Alicante, Spain, and investigator
for the MEASURE-AD study. "These real-world analyses underscore the
multidimensional burden of atopic dermatitis and the need for more
therapeutic options for patients."
Evaluation of Real-World Burden
for Moderate to Severe Atopic Dermatitis in Patients with or
without Systemic Therapy
This post-hoc analysis titled, "Real-World Burden in Patients
with Atopic Dermatitis Who Are Candidates for Systemic Therapy and
Currently Receiving No Systemic Therapy, No Treatment, Topical
Therapy Only, or Systemic Therapy: Results from a Real-World
Multicountry Study," showed greater clinical, psychosocial
and economic burden among adult patients with moderate to severe
atopic dermatitis not receiving systemic therapy versus those
receiving systemic therapy.1 Additionally, data
suggested that many patients living with atopic dermatitis may be
undertreated, with only half of eligible patients receiving
systemic therapy.1
Mean disease severity scores across six measures* were higher
for patients receiving no systemic therapy versus those receiving
systemic therapy (all p<0.0001), with the subset of patients
receiving no treatment generally having the highest mean
scores.1 Additionally, patients who received systemic
therapy reported significantly better DLQI scores, Short-Form
Health Survey Mental Health Component Summary (SF-12 MCS) mean
scores and Physical Component Summary (SF-12 PCS) mean scores
versus patients not receiving systemic therapy
(p<0.0001).1 Overall work productivity impairment and
hours missed from work were also greater among patients receiving
no systemic therapy versus patients receiving systemic therapy
(p<0.0001).1
Examining the Link Between
Patient-Reported Quality of Life and Disease Burden in Atopic
Dermatitis
A separate analysis from MEASURE-AD titled, "Associations
Between Patient-Reported Outcomes and Disease Severity Measures
with Disease Burden in Atopic Dermatitis: Results from a Real-World
Multicountry Study," evaluated how improvements in a patient's
quality of life and low disease severity often lead to lower
clinical burden of disease and work impairment.2 In this
analysis, patients were stratified by patient-reported effect on
quality of life – assessed using DLQI and disease severity measures
(Patient-Oriented Eczema Measure categories [POEM] and the Atopic
Dermatitis Symptom Scale 7-Item Total Symptom Score categories
[ADerm-SS TSS-7]).2 Clinical burden was assessed using
Eczema Area and Severity Index (EASI) and Worst Pruritus Numeric
Rating Scale (WP-NRS).2 Work Productivity and Activity
Impairment-AD (WPAI-AD) measures absenteeism, presenteeism, overall
work productivity impairment and activity impairment.
Results from this analysis showed that EASI and WP-NRS scores
were lower among patients with lower DLQI, lower POEM and lower
ADerm-SS TSS-7 score categories (p<0.0001 for each).2
Similarly, overall work productivity impairment was lower among
patients with lower DLQI, lower POEM and lower ADerm-SS TSS-7 score
categories (p<0.0001 for each).2 Trends for
absenteeism, presenteeism and activity impairment were similar to
those for overall work productivity impairment (all
p<0.0001).2
"Patients are our purpose – their needs fuel our passion to
propel dermatology research forward. The results of these studies
help shed light on the cumulative impact of atopic dermatitis on
patients' quality of life," said Chiedzo Mpofu, MBChB, Ph.D., vice
president, Global Medical Affairs, Immunology, AbbVie. "We're proud
to help advance understanding of the real-world experience of those
living with atopic dermatitis, to uncover disparities in outcomes
and inspire efforts to develop and deliver therapies to
patients."
About MEASURE-AD
1,2,3
MEASURE-AD was a cross-sectional, 28-country study that
characterized the real-world burden of moderate to severe atopic
dermatitis in adolescent and adult patients (≥12 years of age) with
physician-confirmed atopic dermatitis who were either candidates
for or who were receiving systemic therapy. Patients were enrolled
between December 2019 and
December 2020 in 28 countries, with a
total of 1,558 patients enrolled, consisting of 1,434 adults (≥18
years of age) as well as 124 adolescents (12 to 17 years) with
moderate to severe atopic dermatitis receiving or who were eligible
for systemic therapy.
About AbbVie in
Dermatology
For more than a decade, AbbVie has worked to uncover new
solutions and improve care for people with serious skin diseases,
including psoriasis, psoriatic arthritis, hidradenitis suppurativa
and atopic dermatitis. With a broad clinical trial program, we
continue to actively research and adapt to the evolving needs of
the dermatology community and advance our pipeline to help people
achieve their treatment goals and live beyond their skin disease.
For more information on AbbVie in dermatology,
visit https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/dermatology.html.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com. Follow @abbvie on
Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking
Statements
Some statements in this news release are, or may be
considered, forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project" and similar expressions, among
others, generally identify forward-looking statements. AbbVie
cautions that these forward-looking statements are subject to risks
and uncertainties that may cause actual results to differ
materially from those indicated in the forward-looking statements.
Such risks and uncertainties include, but are not limited to,
failure to realize the expected benefits from AbbVie's acquisition
of Allergan plc ("Allergan"), failure to promptly and effectively
integrate Allergan's businesses, competition from other products,
challenges to intellectual property, difficulties inherent in the
research and development process, adverse litigation or government
action, changes to laws and regulations applicable to our industry
and the impact of public health outbreaks, epidemics or pandemics,
such as COVID-19. Additional information about the economic,
competitive, governmental, technological and other factors that may
affect AbbVie's operations is set forth in Item 1A, "Risk Factors,"
of AbbVie's 2021 Annual Report on Form 10-K, which has been filed
with the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
References:
- Silvestre, J.F., et al. Real-World Burden in Patients With
Atopic Dermatitis Who Are Candidates for Systemic Therapy and
Currently Receiving No Systemic Therapy, No Treatment, Topical
Therapy Only, or Systemic Therapy: Results From a Real-World
Multicountry Study. FC02.02. 2022European Academy of Dermatology
and Venereology (EADV) Hybrid Congress.
- Gooderham, M., et al. Associations Between Patient-Reported
Outcomes and Disease Severity Measures With Disease Burden in
Atopic Dermatitis: Results From a Real-World Multicountry Study.
P0286. 2022 European Academy of Dermatology and Venereology (EADV)
Hybrid Congress.
- Eyerich, K., et al. The Burden of Flare in Atopic Dermatitis:
Results From a Multi-Country Study. P0229. 2021 EADV Meeting. 2021
European Academy of Dermatology and Venereology (EADV)
Congress.
- Kapur, S., et al. Allergy Asthma Clin Immunol.
2018;14(Suppl 2):52.
- Drucker, A.M. Allergy Asthma Proc. 2017;38(1):3-8.
- Weidinger, S. and Novak, N. Atopic Dermatitis. Lancet.
2016 Mar 12;387(10023):1109-1122.doi:
10.1016/S0140-6736(15)00149-X. Epub 2015 Sep 13.
- Eicheneld L.F., Tom W.L., Chamlin S.L., et al. Guidelines of
care for the management of atopic dermatitis: section 1. Diagnosis
and assessment of atopic dermatitis. J Am Acad
Dermatol. 2014;70(2):338-351.
doi:10.1016/j.jaad.2013.10.010.
* Measures included Eczema Area and Severity Index (EASI), Worst
Pruritus Numeric Rating Scale (WP-NRS), Validated Investigator
Global Assessment for AD (vlGA-AD), body surface area affected
(BSA), average hours slept per night and number of participants
with inadequately controlled atopic dermatitis.
View original
content:https://www.prnewswire.com/news-releases/new-measure-ad-analyses-evaluate-clinical-psychosocial-and-economic-burdens-in-atopic-dermatitis-patients-301619636.html
SOURCE AbbVie